THE RETURN OF GEMTUZUMAB.

Here is a drug that was the FDA dis-approved believing it has closed the coffin on it.  But straight from the cemetery, an uproar is coming to rattle the FDA door once again!  The point is while the door closed on Gemtuzumab here in the USA, the European have continued using the drug at least at clinical trial basis.  Evidence suggesting that when added to Cytarabine, Gentuzumab could double or triple 2 year survival and increase by 10 months overall survival, is hard to conceal or reject.  This has forced Americans to reconsider, new clinical trial has been re-completed here, and soon the FDA has to convene for these new indications!